A DNA change found in plasma may come from blood cells rather than a tumor. Establishing where a change came from is part of interpreting a liquid biopsy.
A primary study compared plasma cell-free DNA, matched white blood cells and tumor samples and found substantial contributions from clonal hematopoiesis to plasma variants. Matched blood-cell sequencing helped attribute origin. A technically real somatic variant is not necessarily tumor-derived, and origin cannot be assigned from the gene name alone. This measurement problem is distinct from assessing the future health implications of a blood-cell clone.
Showing the technology this term belongs to: Liquid biopsy (ctDNA).
Shares Analytical versus clinical validation, Evidence from measurement to patient benefit, Circulating tumour DNA (ctDNA), Liquid biopsy (ctDNA).
Shares Analytical versus clinical validation, Evidence from measurement to patient benefit.
Shares Analytical versus clinical validation, Evidence from measurement to patient benefit.
Shares Analytical versus clinical validation, Evidence from measurement to patient benefit.
Shares Clonal haematopoiesis (CHIP), Circulating tumour DNA (ctDNA), Liquid biopsy (ctDNA).
Shares Evidence from measurement to patient benefit, Circulating tumour DNA (ctDNA), Liquid biopsy (ctDNA).
Shares Analytical versus clinical validation, Evidence from measurement to patient benefit.
Shares Variant allele frequency (VAF), Circulating tumour DNA (ctDNA), Liquid biopsy (ctDNA).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/